We are led by an exceptional team of drug development and microbiome experts with vast experience in the discovery, development, regulatory approval, and successful commercialization of a wide range of therapeutic products.
Roger Pomerantz, M.D.
President, Chief Executive Officer, and Chairman of the Board of Directors
Roger Pomerantz is the President, Chief Executive Officer, and Chairman of the Board of Directors of Seres Therapeutics, Inc. ("Seres"). Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an internationally recognized expert in HIV molecular pathogenesis and latency. He has developed nine approved infectious disease drugs in important diseases including HIV, HCV, and tuberculosis.
John Aunins Ph.D.
Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
John Aunins is the Executive Vice President of Bioprocess & Manufacturing and the Chief Technology Officer of Seres Therapeutics, Inc. ("Seres"). He has more than 26 years of experience in the biotechnology industry, with a focus in bioprocess development, manufacturing support, and project leadership. Prior to joining Seres, he led process and product development teams at Merck Research Laboratories for Vaqta®, Varivax®, Zostavax®, ProQuad®, Rotateq®, and Gardasil®. The Vaqta and Gardasil process teams were awarded with ACS Industrial Biotechnology Awards for innovation, contribution to bioengineering, and societal impact. He is a Fellow of the American Institute for Medical and Biological Engineering, and an adjunct Full Professor at the Instituto de Tecnologia Química e Biológica (ITQB) in Oeiras, Portugal. He has authored over 50 articles and book chapters, and has chaired five international conferences in vaccines and bioprocess technology. Dr. Aunins earned his Ph.D. in chemical engineering from MIT in 1989 under Institute Professor Daniel I.C. Wang.
David Cook, Ph.D.
Executive Vice President of Research & Development and Chief Scientific Officer
David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.
Executive Vice President and Chief Commercial Officer
Wa'el Hashad is the Executive Vice President and Chief Commercial Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a commercial leader and has held senior marketing and general management positions in the pharmaceutical and biotechnology industry throughout his career. Prior to joining Seres, he served as Regional General Manager for Middle East and Africa at Amgen. Prior to that he served as Head of Global Marketing for General Medicine. Prior to Amgen, Wa’el worked at Boehringer Ingelheim and Eli Lilly where he launched several products in the US, most notably Pradaxa® and Cymbalta®. Wa’el brings significant sales, marketing, market access, and diverse therapeutic expertise in both the US and international markets. He earned his undergraduate degree from College of Pharmacy Cairo University and his MBA from the University of Akron, Ohio.
Executive Vice President and Chief Financial Officer
Eric Shaff is the Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. ("Seres"). He has more than 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance, and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his M.B.A. with a concentration in finance from the Johnson Graduate School of Management at Cornell University.
Michele (Shelley) Trucksis, Ph.D., M.D.
Executive Vice President and Chief Medical Officer
Michele (Shelley) Trucksis is the Executive Vice President and Chief Medical Officer of Seres Therapeutics, Inc. ("Seres"). Dr. Trucksis has 25 years of experience in medicine and infectious diseases. Prior to joining Seres, she served as Executive Director of Merck Research Laboratories with responsibility for clinical and global product development functions and development strategy in antibacterials, antifungals, and anti-cytomegalovirus drug candidates. Dr. Trucksis earned her B.S. in medical technology from Youngstown State University, her Ph.D. in biochemistry from Kent State University, and her M.D. from Case Western Reserve School of Medicine. She completed her internship and residency in Internal Medicine at Yale-New Haven Hospital and her infectious diseases fellowship training at the Massachusetts General Hospital of Harvard Medical School.
Matthew Henn, Ph.D.
Senior Vice President, Head of Drug Discovery & Bioinformatics
Matthew Henn is the Senior Vice President and Head of Drug Discovery & Bioinformatics of Seres Therapeutics, Inc. ("Seres"). He has more than 16 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. Dr. Henn's research has focused on the development, implementation, and application of genomic technologies in the area of microbial populations and their metabolic functions. Prior to joining Seres, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.
He has authored over 60 peer-reviewed publications in microbiology and bioinformatics, and has led multiple large-scale international genomic projects. He has served as a consultant for the WHO’s Grand Challenges in Genomics for Public Health in Developing Countries, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of many peer-reviewed journals. Dr. Henn earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in microbiology at Duke University.
Vice President of Business Development
Henry Rath is the Vice President of Business Development at Seres Therapeutics Inc. ("Seres"). He has over 20 years of experience in the biotechnology industry with roles spanning corporate finance, strategy, and business development. Prior to joining Seres, he worked at Amgen Inc., Catabasis Pharmaceuticals Inc., and Baxter Biopharmaceuticals Inc., and completed licensing and mergers and acquisitions transactions in the United States as well as internationally. Mr. Rath began his career with roles in the banking and consulting industries focusing on biotechnology with Oppenheimer & Co. Inc. and LEK Consulting. Mr. Rath earned his undergraduate degree from Harvard College and his M.B.A. from the Wharton School of the University of Pennsylvania.
Thomas J. DesRosier, Esq.
Executive Vice President, Chief Legal Officer and Secretary
Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, Inc (Seres). He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. He received his J.D. from Wake Forest University School of Law and his Bachelor of Arts in chemistry from the University of Vermont.